Banking Barrens – As Loans Dry Up, Local Companies Scramble for Credit

Stubbornly high interest rates, problem loans and a push by regulators for banks to keep more capital on their books means tighter lending standards. Here’s what that means for companies on the border of being creditworthy and who’s stepping up to save the day.

xperimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected, wiping as much as $125 billion off the company’s value.